Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 11;41(4):790–802. doi: 10.1200/JCO.21.02508

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

FIG 4. — Kaplan-Meier estimates of DOR in patients with a best objective response of CR or PR. Pembrolizumab alone versus cetuximab with chemotherapy in the (A) PD-L1 CPS ≥ 20, (B) PD-L1 CPS ≥ 1, and (C) total populations at long-term follow-up and pembrolizumab with chemotherapy versus cetuximab with chemotherapy in the (D) PD-L1 CPS ≥ 20, (E) PD-L1 CPS ≥ 1, and (F) total populations. ^aFrom the product-limit (Kaplan-Meier) method for censored data. CPS, combined positive score; CR, complete response; DOR, duration of response; IQR, interquartile range; ORR, objective response rate; PD-L1, programmed death ligand 1; PR, partial response.